Long‐term experience using CNI‐free immunosuppression in selected paediatric heart transplant recipients

CNI‐free immunosuppression with conversion to mTORi‐based immunosuppression has been demonstrated to reduce CNI‐toxicity and to exhibit anti‐proliferative properties. However, the experience of CNI‐free immunosuppression in paediatric heart transplantation is limited.

[1]  R. Kozlik-Feldmann,et al.  Conversion to everolimus in pediatric heart transplant recipients is a safe treatment option with an impact on cardiac allograft vasculopathy and renal function , 2020, Clinical transplantation.

[2]  J. Kirklin,et al.  Surveillance for cardiac allograft vasculopathy: Practice variations among 50 pediatric heart transplant centers. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  Byron H. Smith,et al.  Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. , 2019, Journal of the American College of Cardiology.

[4]  J. Stypmann,et al.  Comparing everolimus‐based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from 6 months after heart transplantation: The randomized MANDELA study , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  M. Hosking,et al.  Optical Coherence Tomography for the Early Detection of Coronary Vascular Changes in Children and Adolescents After Cardiac Transplantation: Findings From the International Pediatric OCT Registry. , 2019, JACC. Cardiovascular imaging.

[6]  H. Bøtker,et al.  Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients: Three-Year Results of a Scandinavian Randomized Trial , 2018, Circulation. Heart failure.

[7]  E. Amankwah,et al.  Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation , 2017, Clinical transplantation.

[8]  L. Bailey,et al.  Calcineurin inhibitor‐ and corticosteroid‐free immunosuppression in pediatric heart transplant patients , 2017, Pediatric transplantation.

[9]  C. Shun,et al.  Malignancy After Heart Transplantation Under Everolimus Versus Mycophenolate Mofetil Immunosuppression. , 2016, Transplantation proceedings.

[10]  G. Dellgren,et al.  Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three‐Year Results From the Randomized SCHEDULE Study , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  J. Kobashigawa,et al.  Everolimus in Heart Transplantation: Does It Finally Have a Home? , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  S. Amler,et al.  Prospective study of everolimus with calcineurin inhibitor-free immunosuppression after heart transplantation: results at four years. , 2014, The Annals of thoracic surgery.

[13]  D. Driscoll,et al.  Empiric switch from calcineurin inhibitor to sirolimus‐based immunosuppression in pediatric heart transplantation recipients , 2013, Pediatric transplantation.

[14]  A. Angelini,et al.  The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[15]  D. Kobayashi,et al.  Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients , 2013, Pediatric transplantation.

[16]  M. Burch,et al.  Sirolimus – Moving toward the mainstream in pediatric heart transplantation? , 2012, Pediatric transplantation.

[17]  J. Thul,et al.  Renal function in children with heart transplantation after switching to CNI‐free immunosuppression with everolimus , 2011, Pediatric transplantation.

[18]  S. Amler,et al.  Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years' follow-up from the University Hospital Münster. , 2011, Transplantation proceedings.

[19]  R. Hetzer,et al.  Pediatric heart transplantation: 23-year single-center experience. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[20]  J. Chapman.  Chronic Calcineurin Inhibitor Nephrotoxicity—Lest We Forget , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  B. McCrindle,et al.  Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[22]  J. Gossett,et al.  Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: Intermediate experience in pediatric heart transplantation recipients , 2010, Pediatric transplantation.

[23]  W. Hörl,et al.  The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  Susan L Furth,et al.  New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[25]  R. Hetzer,et al.  Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[26]  R. Hetzer,et al.  Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  M. Vaysberg,et al.  Rapamycin Inhibits Proliferation of Epstein-Barr Virus–Positive B-cell Lymphomas Through Modulation of Cell-Cycle Protein Expression , 2007, Transplantation.

[28]  Silviu Itescu,et al.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[29]  V. Ng,et al.  Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma * , 2004, Pediatric transplantation.

[30]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[31]  D. Goldstein,et al.  Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. , 1997, Transplantation.

[32]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .